The Globe and Mail argues the retatrutide pipeline matters more to Lilly than the quarter itself, as Mounjaro and Zepbound keep revenue climbing.
Recap by typeshit. Full story at The Globe and Mail.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
An analysis argues the TRIUMPH-2 results for Lilly's retatrutide should change how metabolic trials are set up.
The Phase III trial tested Lilly's once-weekly triple receptor agonist for efficacy and safety in people with obesity and type 2 diabetes.
Loading…